Bavarian Nordic (OTCMKTS:BVNRY) Shares Cross Above 50 Day Moving Average – Here’s Why

Shares of Bavarian Nordic (OTCMKTS:BVNRY) crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $10.08 and traded as high as $10.2650. Bavarian Nordic shares last traded at $10.2650, with a volume of 195 shares trading hands.

Bavarian Nordic Stock Up 0.7%

The stock has a market capitalization of $2.44 billion, a PE ratio of 6.62 and a beta of 1.36. The firm has a 50 day moving average price of $10.08 and a 200 day moving average price of $11.10.

Bavarian Nordic (OTCMKTS:BVNRY) last posted its quarterly earnings data on Friday, November 14th. The company reported $0.72 earnings per share (EPS) for the quarter. Bavarian Nordic had a net margin of 35.96% and a return on equity of 20.47%. The firm had revenue of $281.11 million for the quarter. On average, equities analysts forecast that Bavarian Nordic will post 0.67 earnings per share for the current fiscal year.

Bavarian Nordic Company Profile

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.